Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Type: Poster Session

Time: Monday June 5, 8:00 AM to 11:30 AM

Location: Hall A


Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Type: Poster Discussion Session

Time: Monday June 5, 3:00 PM to 4:15 PM

Location: E354b

Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.

Sub-category:
Multiple Myeloma

Category:
Hematologic Malignancies—Plasma Cell Dyscrasia

Meeting:
2017 ASCO Annual Meeting

Abstract No:
8011

Poster Board Number:
Poster Discussion Session (Board #337)

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 8011)

Author(s): Stefania Oliva, Davine Hofste op Bruinink, Lucie ŘÍhová, Stefano Spada, Bronno van der Holt, Rossella Troia, Manuela Gambella, Lucia Pantani, Sara Grammatico, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Antonio Palumbo, Michele Cavo, Paola Omedè, Vincent van der Velden, Mario Boccadoro, Pieter Sonneveld; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy; Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands; Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Hematology, Erasmus Medical Center Cancer Institute, HOVON Data Center, Rotterdam, Netherlands; Italian Multiple Myeloma Network, Gimema, Italy; Department of Haematooncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic; Department of Immunology, Erasmus Medical Center, Rotterdam, Netherlands

Abstract Disclosures

Abstract:

Background: MRD detection is a sensitive tool to measure response in MM. We assessed MRD by MFC in newly diagnosed MM patients (pts) enrolled in the EMN02/HO95 phase 3 trial. Methods: Pts were ≤65 years old and received Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction, intensification with Bortezomib-Melphalan-Prednisone (VMP) vs High-Dose-Melphalan (HDM) followed by stem cell transplant, consolidation with Bortezomib-Lenalidomide-Dexamethasone (VRD) vs no consolidation, and Lenalidomide maintenance. MRD analysis was performed in pts achieving at least a very good partial response (VGPR) before starting maintenance (after HDM, VMP or VRD) and during maintenance every 6-12 months; samples were centralized to 3 European labs. MFC was performed on bone marrow according to Euroflow-based methods (8 colors, 2 tubes) with a sensitivity of 10-5. Quality checks were performed to compare sensitivity and to show correlation between protocols (Hofste op Bruinink D ASH 2016 abstract 2072). Results: 316 pts were evaluable before maintenance: median age was 57 years, 18% (57/316) pts had ISS III and 22% (70/316) had high risk cytogenetic (HR-C) defined as having at least one among del17, t(4;14) or t(14;16); 63% (199/316) had received HDM and 37% (117/316) VMP; thereafter 51% (160/316) had received VRD. 76% (239/316) were MRD negative (MRD-) of whom 64% (153/239) received HDM vs 36% (86/239) VMP, with a median follow-up time of 30 months from MRD enrolment. 3-year PFS was 50% in MRD positive (MRD+) vs 77% in MRD- pts (HR: 2.87, p < 0.001). Subgroup analyses were performed to evaluate the risk factors for MRD+ according to baseline characteristics and therapies: HR-C was the most important risk factor (HR 9.87, interaction-p = 0.001). Finally, 48% of MRD+ pts at pre-maintenance who had a second MRD evaluation after at least 1 year of lenalidomide became MRD-. Conclusions: MRD by MFC is a strong prognostic factor in MM pts receiving intensification with novel agents or transplant; lenalidomide maintenance further improved depth of response; HR-C is the most important prognostic factor in MRD+ pts. Clinical trial information: NCT01208766

 
Other Abstracts in this Sub-Category:

 

1. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8000 First Author: Andrzej J. Jakubowiak
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

2. Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8001 First Author: Stefan Knop
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

3. An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8002 First Author: Jacob Laubach
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

More...